PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Dec 30, 2023 to Dec 30, 2024v5
  3. Re-verified, no change to tracked fieldsv4
  4. Primary completion date: Dec 30, 2020 to Dec 30, 2023
    • Study completion date: Dec 31, 2020 to Dec 31, 2024
    v3
  5. Eligibility criteria shortened, about 16 wordsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Trial Details
NCT Number NCT04144569
Lead Sponsor Yongchang Zhang
Conditions
(from sponsor)		 HER2 Insertion Mutation Positive Advanced NSCLC
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov